Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 63405 [2021-24895]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 218 / Tuesday, November 16, 2021 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
The U.S. Department of
Health and Human Services is hereby
giving notice that the Advisory
Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a
virtual meeting. The meeting will be
open to the public. For this meeting, the
committee will discuss and vote on a
recommendation pertaining to a
proposed update to the 2020 Public
Health Service (PHS) Guideline for
Assessing Solid Organ Donors and
Monitoring Transplant Recipients for
Human Immunodeficiency Virus,
Hepatitis B Virus, and Hepatitis C Virus
Infection. The following question will
be posed to the committee: Does the
available data support exempting solid
organ transplant candidates who are ≤10
years of age at the time of transplant
(and who have received postnatal
infectious disease testing) from the
recommendation for HIV, Hepatitis B
virus, and Hepatitis C virus testing
during the hospital admission for
transplant but prior to anastomosis of
the first organ?
DATES: The meeting will take place
virtually on Wednesday, December 1,
2021 from approximately 11:00 a.m.–
3:00 p.m. Eastern Time (ET). Meeting
times are tentative and subject to
change. The confirmed times and
agenda items for the meeting will be
posted on the ACBTSA web page at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2021-12-01/
index.html when this information
becomes available.
FOR FURTHER INFORMATION CONTACT:
James Berger, Designated Federal Officer
for the ACBTSA; Office of Infectious
Disease and HIV/AIDS Policy, Office of
the Assistant Secretary for Health,
Department of Health and Human
Services, Mary E. Switzer Building, 330
C Street SW, Suite L600, Washington,
DC 20024. (202) 795–7608 or Email:
ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBTSA is a discretionary Federal
advisory committee. The Committee is
governed by the provisions of the
Federal Advisory Committee Act
(FACA), Public Law 92–463, as
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:03 Nov 15, 2021
Jkt 256001
amended (5 U.S.C. App), which sets
forth standards for the formation and
use of advisory committees. On the day
of the meeting, please go to https://
www.hhs.gov/live/ to view
the meeting. The public will have an
opportunity to present their views to the
ACBTSA by submitting a written public
comment. Comments should be
pertinent to the meeting discussion.
Persons who wish to provide written
public comment should review
instructions at https://www.hhs.gov/
oidp/advisory-committee/blood-tissuesafety-availability/meetings/2021-12-01/
index.html and respond by midnight
November 26, 2021, ET. Written public
comments will be accessible to the
public on the ACBTSA web page prior
to the meeting.
ACBTSA functions to provide advice
to the Secretary through the Assistant
Secretary for Health on a range of policy
issues to include: (1) Identification of
public health issues through
surveillance of blood and tissue safety
issues with national survey and data
tools; (2) identification of public health
issues that affect availability of blood,
blood products, and tissues; (3) broad
public health, ethical, and legal issues
related to the safety of blood, blood
products, and tissues; (4) the impact of
various economic factors (e.g., product
cost and supply) on safety and
availability of blood, blood products,
and tissues; (5) risk communications
related to blood transfusion and tissue
transplantation; and (6) identification of
infectious disease transmission issues
for blood, organs, blood stem cells and
tissues. The Committee has met
regularly since its establishment in
1997.
Dated: October 27, 2021.
James J. Berger,
Designated Federal Officer, Advisory
Committee on Blood and Tissue Safety and
Availability, Office of Infectious Disease and
HIV/AIDS Policy.
[FR Doc. 2021–24895 Filed 11–15–21; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Division of
Extramural Research and Training
(DERT) Extramural Grantee Data
Collection (National Institute of
Environmental Health Sciences)
AGENCY:
National Institutes of Health,
HHS.
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
ACTION:
63405
Notice.
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Kristianna
Pettibone, Evaluator, Program Analysis
Branch, NIEHS, NIH, 530 Davis Dr.,
Room 3064, Morrisville, NC 20560, or
call non-toll-free number 984–287–3303
or Email your request, including your
address to: pettibonekg@niehs.nih.gov.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on September 13, 2021,
Volume 86, Number 74, page 50897–
50898 and allowed 60-days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Institute of
Environmental Health Sciences
(NIEHS), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: DERT
Extramural Grantee Data Collection,
0925–0757– REVISION—Expiration
Date 11/30/2021, National Institute of
Environmental Health Sciences
ADDRESSES:
E:\FR\FM\16NON1.SGM
16NON1
]]>Agencies
[Federal Register Volume 86, Number 218 (Tuesday, November 16, 2021)]
[Notices]
[Page 63405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24895]
[[Page 63405]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Office of the Assistant Secretary for Health, Office of the
Secretary, Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The U.S. Department of Health and Human Services is hereby
giving notice that the Advisory Committee on Blood and Tissue Safety
and Availability (ACBTSA) will hold a virtual meeting. The meeting will
be open to the public. For this meeting, the committee will discuss and
vote on a recommendation pertaining to a proposed update to the 2020
Public Health Service (PHS) Guideline for Assessing Solid Organ Donors
and Monitoring Transplant Recipients for Human Immunodeficiency Virus,
Hepatitis B Virus, and Hepatitis C Virus Infection. The following
question will be posed to the committee: Does the available data
support exempting solid organ transplant candidates who are <=10 years
of age at the time of transplant (and who have received postnatal
infectious disease testing) from the recommendation for HIV, Hepatitis
B virus, and Hepatitis C virus testing during the hospital admission
for transplant but prior to anastomosis of the first organ?
DATES: The meeting will take place virtually on Wednesday, December 1,
2021 from approximately 11:00 a.m.-3:00 p.m. Eastern Time (ET). Meeting
times are tentative and subject to change. The confirmed times and
agenda items for the meeting will be posted on the ACBTSA web page at
https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-12-01/ when this information
becomes available.
FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS
Policy, Office of the Assistant Secretary for Health, Department of
Health and Human Services, Mary E. Switzer Building, 330 C Street SW,
Suite L600, Washington, DC 20024. (202) 795-7608 or Email:
[email protected].
SUPPLEMENTARY INFORMATION: The ACBTSA is a discretionary Federal
advisory committee. The Committee is governed by the provisions of the
Federal Advisory Committee Act (FACA), Public Law 92-463, as amended (5
U.S.C. App), which sets forth standards for the formation and use of
advisory committees. On the day of the meeting, please go to https://www.hhs.gov/live/ to view the meeting. The public will have
an opportunity to present their views to the ACBTSA by submitting a
written public comment. Comments should be pertinent to the meeting
discussion. Persons who wish to provide written public comment should
review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2021-12-01/ and
respond by midnight November 26, 2021, ET. Written public comments will
be accessible to the public on the ACBTSA web page prior to the
meeting.
ACBTSA functions to provide advice to the Secretary through the
Assistant Secretary for Health on a range of policy issues to include:
(1) Identification of public health issues through surveillance of
blood and tissue safety issues with national survey and data tools; (2)
identification of public health issues that affect availability of
blood, blood products, and tissues; (3) broad public health, ethical,
and legal issues related to the safety of blood, blood products, and
tissues; (4) the impact of various economic factors (e.g., product cost
and supply) on safety and availability of blood, blood products, and
tissues; (5) risk communications related to blood transfusion and
tissue transplantation; and (6) identification of infectious disease
transmission issues for blood, organs, blood stem cells and tissues.
The Committee has met regularly since its establishment in 1997.
Dated: October 27, 2021.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue
Safety and Availability, Office of Infectious Disease and HIV/AIDS
Policy.
[FR Doc. 2021-24895 Filed 11-15-21; 8:45 am]
BILLING CODE 4150-28-P
